tulobuterol has been researched along with Pulmonary Disease, Chronic Obstructive in 14 studies
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In COPD patients, additional administration of transdermal tulobuterol to inhaled tiotropium produced significant benefits in dyspnea and SGRQ score as well as pulmonary function." | 5.14 | Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD. ( Fukuchi, Y; Ichinose, M; Kubo, K; Mishima, M; Nagai, A; Nishimura, M; Seyama, K, 2010) |
| " We examined the effect of adding a long-acting anti-cholinergic agent (tiotropium) to a transdermal-type beta(2)-agonist (tulobuterol) on dyspnea as well as pulmonary function." | 5.12 | Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal beta(2)-agonist. ( Akamatsu, K; Hirano, T; Ichikawa, T; Ichinose, M; Maeda, S; Matsunaga, K; Minakata, Y; Miura, K; Nakanishi, M; Takahashi, T; Ueshima, K; Yamagata, T; Yamagata, Y; Yanagisawa, S, 2007) |
| "Treatment-naïve patients with COPD (n = 36) were prospectively treated with two kinds of LABA--inhaled salmeterol and transdermal tulobuterol patch--for 12 weeks in crossover study, and changes in pulmonary function data and 6-minute walk distance (6 MWD) were compared between groups stratified by the CysGlyGln." | 2.77 | β2-adrenergic receptor haplotype may be associated with susceptibility to desensitization to long-acting β2-agonists in COPD patients. ( Kawate, E; Mochizuki, H; Nanjo, Y; Takahashi, H; Tsuda, Y; Yamazaki, M, 2012) |
| "The airway inflammation of chronic obstructive pulmonary disease (COPD) demonstrates a poor response to the anti-inflammatory actions of corticosteroids." | 2.73 | Anti-inflammatory effects and clinical efficacy of theophylline and tulobuterol in mild-to-moderate chronic obstructive pulmonary disease. ( Haruta, Y; Hattori, N; Ishikawa, N; Iwamoto, H; Kanehara, M; Kohno, N; Shiota, N; Taooka, Y; Tomoda, Y; Yokoyama, A, 2008) |
| "Transdermal beta 2-agonist tulobuterol showed an improvement in FEV1, FVC and IC after dosing compared with those at baseline." | 2.73 | Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ( Akamatsu, K; Hirano, T; Ichikawa, T; Ichinose, M; Matsunaga, K; Minakata, Y; Nakanishi, M; Sugiura, H; Ueshima, K; Yamagata, T; Yanagisawa, S, 2008) |
| "Treatment of COPD patients with TP is more effective than with theophylline." | 2.73 | Clinical efficacy of the transdermal tulobuterol patch in patients with chronic obstructive pulmonary disease: a comparison with slow-release theophylline. ( Aizawa, H; Gohara, R; Ichiki, M; Iwanaga, T; Kawayama, T; Kinoshita, M; Koga, H; Minami, S; Nishiyama, M; Sueyasu, Y, 2008) |
| "Clinically stable COPD patients (age > or = 40 years, postbronchodilator FEV1/FVC <70%, and postbronchodilator FEV1 <80% predicted) were enrolled in a multicenter, open-label randomized study." | 2.71 | Clinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD: an open-label comparison with inhaled salmeterol. ( Aizawa, H; Fukuchi, Y; Hirata, K; Ichinose, M; Kubo, K; Nagai, A; Nishimura, M; Seyama, K, 2005) |
| "Changing PA behavior in COPD patients requires an interdisciplinary approach involving specialists in respiratory medicine, rehabilitation, social, and behavioral sciences." | 2.58 | Improvement of physical activity in chronic obstructive pulmonary disease by pulmonary rehabilitation and pharmacological treatment. ( Iwakura, M; Satake, M; Sato, S; Shioya, T; Takahashi, H; Terui, Y; Uemura, S, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuo, Y | 1 |
| Jo, T | 1 |
| Makito, K | 1 |
| Matsui, H | 1 |
| Fushimi, K | 1 |
| Yasunaga, H | 1 |
| Ogasawara, T | 1 |
| Sakata, J | 1 |
| Aoshima, Y | 1 |
| Tanaka, K | 1 |
| Yano, T | 1 |
| Kasamatsu, N | 1 |
| Shioya, T | 1 |
| Sato, S | 1 |
| Iwakura, M | 1 |
| Takahashi, H | 4 |
| Terui, Y | 1 |
| Uemura, S | 1 |
| Satake, M | 1 |
| Kanehara, M | 1 |
| Yokoyama, A | 1 |
| Tomoda, Y | 1 |
| Shiota, N | 1 |
| Iwamoto, H | 1 |
| Ishikawa, N | 1 |
| Taooka, Y | 1 |
| Haruta, Y | 1 |
| Hattori, N | 1 |
| Kohno, N | 1 |
| Sugawara, T | 1 |
| Nanjo, Y | 3 |
| Yamazaki, M | 2 |
| Higashihara, K | 1 |
| Tsuda, Y | 2 |
| Mochizuki, H | 3 |
| Noguchi, T | 1 |
| Ichinose, M | 5 |
| Seyama, K | 2 |
| Nishimura, M | 2 |
| Fukuchi, Y | 3 |
| Nagai, A | 2 |
| Mishima, M | 1 |
| Kubo, K | 2 |
| Abe, T | 1 |
| Setoguchi, Y | 1 |
| Kono, Y | 1 |
| Togashi, Y | 1 |
| Sugiyama, S | 1 |
| Tanakadate, M | 1 |
| Soeda, S | 1 |
| Nakai, M | 1 |
| Sugiyama, N | 1 |
| Fujiwara, A | 1 |
| Yamaguchi, K | 1 |
| Yamaguchi, A | 1 |
| Kurita, N | 1 |
| Tamura, G | 1 |
| Miyamoto, T | 1 |
| Kawate, E | 1 |
| Hirata, K | 1 |
| Aizawa, H | 2 |
| Akamatsu, K | 2 |
| Yamagata, T | 2 |
| Takahashi, T | 1 |
| Miura, K | 1 |
| Maeda, S | 1 |
| Yamagata, Y | 1 |
| Ichikawa, T | 2 |
| Yanagisawa, S | 2 |
| Ueshima, K | 2 |
| Hirano, T | 2 |
| Nakanishi, M | 2 |
| Matsunaga, K | 2 |
| Minakata, Y | 2 |
| Sugiura, H | 1 |
| Minami, S | 1 |
| Kawayama, T | 1 |
| Ichiki, M | 1 |
| Nishiyama, M | 1 |
| Sueyasu, Y | 1 |
| Gohara, R | 1 |
| Kinoshita, M | 1 |
| Koga, H | 1 |
| Iwanaga, T | 1 |
2 reviews available for tulobuterol and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Improvement of physical activity in chronic obstructive pulmonary disease by pulmonary rehabilitation and pharmacological treatment.
Topics: Adrenergic beta-2 Receptor Agonists; Behavior; Counseling; Delayed-Action Preparations; Drug Therapy | 2018 |
Transdermal tulobuterol patch, a long-actingβ(2)-agonist.
Topics: Adrenergic beta-Agonists; Asthma; Bronchodilator Agents; Drug Approval; Evidence-Based Medicine; Hum | 2012 |
11 trials available for tulobuterol and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Bronchodilator Effect of Tiotropium via Respimat
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Cross-Over Studies; Female; Forced Expirato | 2017 |
Anti-inflammatory effects and clinical efficacy of theophylline and tulobuterol in mild-to-moderate chronic obstructive pulmonary disease.
Topics: Administration, Cutaneous; Adrenergic beta-Agonists; Aged; Anti-Inflammatory Agents, Non-Steroidal; | 2008 |
Comparison of adherence and efficacy between inhaled salmeterol and transdermal tulobuterol patch in elderly patients with chronic obstructive pulmonary disorder.
Topics: Administration, Cutaneous; Administration, Inhalation; Aged; Albuterol; Bronchodilator Agents; Cross | 2009 |
Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD.
Topics: Administration, Cutaneous; Administration, Inhalation; Aged; Bronchodilator Agents; Dose-Response Re | 2010 |
Effects of inhaled tiotropium plus transdermal tulobuterol versus tiotropium alone on impulse oscillation system (IOS)-assessed measures of peripheral airway resistance and reactance, lung function and quality of life in patients with COPD: a randomized c
Topics: Administration, Cutaneous; Administration, Inhalation; Aged; Aged, 80 and over; Airway Resistance; B | 2011 |
β2-adrenergic receptor haplotype may be associated with susceptibility to desensitization to long-acting β2-agonists in COPD patients.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Cross-Over Studies | 2012 |
Better adherence to a transdermal tulobuterol patch than inhaled salmeterol in elderly chronic obstructive pulmonary disease patients.
Topics: Administration, Cutaneous; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenerg | 2013 |
Clinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD: an open-label comparison with inhaled salmeterol.
Topics: Administration, Cutaneous; Administration, Inhalation; Adult; Aged; Albuterol; Bronchodilator Agents | 2005 |
Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal beta(2)-agonist.
Topics: Administration, Cutaneous; Administration, Inhalation; Adrenergic beta-Agonists; Aged; Bronchodilato | 2007 |
Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists.
Topics: Administration, Cutaneous; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Al | 2008 |
Clinical efficacy of the transdermal tulobuterol patch in patients with chronic obstructive pulmonary disease: a comparison with slow-release theophylline.
Topics: Activities of Daily Living; Administration, Cutaneous; Aged; Aged, 80 and over; Bronchodilator Agent | 2008 |
1 other study available for tulobuterol and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Association between use of transdermal tulobuterol and short-term outcomes in patients with stroke and underlying chronic obstructive pulmonary disease: A retrospective cohort study.
Topics: Hospital Mortality; Humans; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Stroke | 2023 |